×
About 96 results

ALLMedicine™ Acquired Generalized Lipodystrophy Center

Research & Reviews  39 results

Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and co...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904732
Nature Communications; Ziegler JF, Böttcher C et. al.

Dec 11th, 2019 - Leptin has been shown to modulate intestinal inflammation in mice. However, clinical evidence regarding its immune-stimulatory potential in human Crohn's disease remains sparse. We here describe a patient with the unique combination of acquired ge...

Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
https://doi.org/10.2337/dc18-2535
Diabetes Care; Jehl A, Cugnet-Anceau C et. al.

Aug 22nd, 2019 - Anti-programmed cell death-1 (anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD-1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations, including acute-onset type 1 diabetes. Acq...

Acquired generalized lipodystrophy under immune checkpoint inhibition.
https://doi.org/10.1111/bjd.18124
The British Journal of Dermatology References; Haddad N, Vidal-Trecan T et. al.

May 11th, 2019 - Immune checkpoint inhibitors are now the standard of care in the treatment of several types of cancer. Cutaneous immune-related adverse events (irAEs) are usually of low grade and reversible, while endocrine irAEs are generally irreversible and ma...

Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell ...
https://doi.org/10.1210/jc.2018-02221
The Journal of Clinical Endocrinology and Metabolism; Falcao CK, Cabral MCS et. al.

Feb 19th, 2019 - Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report a case of acquired generalized lipodystrophy possibly associated with nivolumab. A woman was referred to our Endocrinology Departm...

Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immun...
https://doi.org/10.1210/jc.2018-00494
The Journal of Clinical Endocrinology and Metabolism; Halpern B, Nery M et. al.

May 30th, 2018 - Acquired generalized lipodystrophy (AGL), a rare disorder characterized by loss of subcutaneous adipose tissue, is estimated to occur in association with autoimmune diseases in ~25% of the cases. Common variable immunodeficiency (CVI) is a conditi...

see more →

Guidelines  1 results

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →

Drugs  4 results see all →

Clinicaltrials.gov  49 results

Myalept - metreleptin injection, powder, lyophilized, for solution-Amryt Pharmaceuticals DAC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c986f93b-855d-4ef0-b620-5d41a0513e48

Sep 27th, 2020 - MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. (1) Limitations of Use The safety and effectivenes...

Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and co...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904732
Nature Communications; Ziegler JF, Böttcher C et. al.

Dec 11th, 2019 - Leptin has been shown to modulate intestinal inflammation in mice. However, clinical evidence regarding its immune-stimulatory potential in human Crohn's disease remains sparse. We here describe a patient with the unique combination of acquired ge...

Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
https://doi.org/10.2337/dc18-2535
Diabetes Care; Jehl A, Cugnet-Anceau C et. al.

Aug 22nd, 2019 - Anti-programmed cell death-1 (anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD-1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations, including acute-onset type 1 diabetes. Acq...

Acquired generalized lipodystrophy under immune checkpoint inhibition.
https://doi.org/10.1111/bjd.18124
The British Journal of Dermatology References; Haddad N, Vidal-Trecan T et. al.

May 11th, 2019 - Immune checkpoint inhibitors are now the standard of care in the treatment of several types of cancer. Cutaneous immune-related adverse events (irAEs) are usually of low grade and reversible, while endocrine irAEs are generally irreversible and ma...

Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell ...
https://doi.org/10.1210/jc.2018-02221
The Journal of Clinical Endocrinology and Metabolism; Falcao CK, Cabral MCS et. al.

Feb 19th, 2019 - Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report a case of acquired generalized lipodystrophy possibly associated with nivolumab. A woman was referred to our Endocrinology Departm...

see more →

News  3 results

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.medscape.com/viewarticle/821056

Feb 24th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.staging.medscape.com/viewarticle/821056

Feb 24th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →